Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $10 from $13 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience launches Niagen Plus telehealth plarform
- Niagen Bioscience announces new partnership with Olympia Pharmaceuticals
- Niagen Bioscience collaborates with USP to establish USP monograph
- Niagen announces first cruise ship clinic partnership with OneSpaWorld
- Niagen Bioscience Doubles Share Repurchase Authorization to $20M